CAPTRUST Financial Advisors’s Definium Therapeutics DFTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$477K	Buy	12,529 +381	+3%	+$16.1K	﹤0.01%	2265
2026 Q2	$571K	Buy	+12,148	New	+$300K	﹤0.01%	2079
2022 Q3	–	Sell	-837	Closed	-$8K	–	3260
2022 Q2	$8K	Buy	837 +585	+232%	+$7.4K	﹤0.01%	3870
2022 Q1	$4K	Sell	252 -67	-21%	-$1.16K	﹤0.01%	4256
2021 Q4	$7K	Buy	319 +49	+18%	+$1.56K	﹤0.01%	3908
2021 Q3	$9K	Buy	270 +1	+0.4%	+$43	﹤0.01%	3675
2021 Q2	$14K	Buy	+269	New	+$14.1K	﹤0.01%	3347

Other funds holding DFTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

CAPTRUST Financial Advisors's DFTX Position: Q3 2026 in Review

CAPTRUST Financial Advisors increased its Definium Therapeutics (DFTX) stake by 3.1% in Q3 2026, buying an estimated $16.1K and bringing the position to 12,529 shares worth $477K. The position accounts for ﹤0.01% of the portfolio, ranked #2265.

CAPTRUST Financial Advisors first reported a position in DFTX in Q2 2021 and has held it in 7 quarters since. The position peaked at $571K in Q2 2026. 197 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

CAPTRUST Financial Advisors held 12,529 shares of Definium Therapeutics worth $477K as of Q3 2026.
CAPTRUST Financial Advisors bought 381 Definium Therapeutics shares in Q3 2026, an estimated $16.1K.
Definium Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q3 2026, its #2265 holding.
CAPTRUST Financial Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 7 quarters since.
CAPTRUST Financial Advisors's Definium Therapeutics position peaked at $571K in Q2 2026.
197 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.